通过皮肤糜蛋白酶测试筛选化学核溶解术候选者来预防糜蛋白酶过敏反应。

Prevention of chymopapain anaphylaxis by screening chemonucleolysis candidates with cutaneous chymopapain testing.

作者信息

Grammer L C, Schafer M, Bernstein D, Bernstein I L, Cogen F, Dolovich J, Schatz M, Zeiger R, Shaughnessy J J, Gutt L

机构信息

Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611.

出版信息

Clin Orthop Relat Res. 1988 Sep(234):12-5.

PMID:3409565

Abstract

With chymopapain at a concentration of 10 mg/ml, the authors skin tested 540 chemonucleolysis candidates; six were positive, and 534 were negative. None of the positive patients received therapeutic injections of chymopapain. There were no instances of unequivocal anaphylaxis to chymopapain in the patients with negative skin tests treated with chymopapain. When this 0% incidence of systemic reactions in skin test negative patients is compared with the historical rate of 1%, this difference is statistically significant (p less than 0.05). Restriction of chymopapain treatment to patients with negative prick tests can reduce the incidence of systemic reactions.

摘要

作者使用浓度为10毫克/毫升的木瓜凝乳蛋白酶对540名接受化学髓核溶解术的候选患者进行了皮肤测试；6例呈阳性，534例呈阴性。所有阳性患者均未接受木瓜凝乳蛋白酶治疗性注射。在接受木瓜凝乳蛋白酶治疗的皮肤测试阴性患者中，未出现明确的对木瓜凝乳蛋白酶过敏反应的病例。将皮肤测试阴性患者中这种0%的全身反应发生率与1%的历史发生率相比较，这种差异具有统计学意义（p小于0.05）。将木瓜凝乳蛋白酶治疗限制于点刺试验阴性的患者可降低全身反应的发生率。